Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall: A National Cancer Database Analysis-Reference-Cited by-同舟云学术

Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall: A National Cancer Database Analysis

Published:2019-04 Issue: Volume:130 Page:162-168
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Foster Corey C.,Rusthoven Chad G.,Sher David J.^ORCID,Feldman Lawrence,Pasquinelli Mary,Spiotto Michael T.,Koshy Matthew

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference25 articles.

1. Cancer statistics;Siegel;CA Cancer J. Clin.,2018

2. Reduced lung-cancer mortality with low-dose computed tomographic screening;Aberle;N. Engl. J. Med.,2011

3. Long-term results of RTOG 0236: a phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with medically inoperable stage I non-small cell lung cancer;Timmerman;Int. J. Radiat. Oncol. Biol. Phys.,2014

4. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials;Chang;Lancet Oncol.,2015

5. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group;Pignon;J. Clin. Oncol.,2008

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prospective study investigating hypofractionated proton beam therapy in patients with inoperable early stage non-small cell lung cancer;Frontiers in Oncology;2024-02-20

2. Exploring published and novel pre-treatment CT and PET radiomics to stratify risk of progression among early-stage non-small cell lung cancer patients treated with stereotactic radiation;Radiotherapy and Oncology;2024-01

3. Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial;Nature Communications;2023-09-02

4. Impact of radiation dose to the immune system on disease progression and survival for early-stage non-small cell lung cancer treated with stereotactic body radiation therapy;Radiotherapy and Oncology;2023-09

5. Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer;International Journal of Radiation Oncology*Biology*Physics;2023-09